Ioannis Karantas

Dr. Ioannis Karantas

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Asian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
MOMehmet Evren Okur
Mehmet Evren Okur
IKIoannis Karantas
Ioannis Karantas
ZŞZeynep Şenyiğit
Zeynep Şenyiğit
Neslihan Üstündağ OkurNeslihan Üstündağ Okur
Neslihan Üstündağ Okur
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
Wound healing is an unmet therapeutic challenge among medical society since wound assessment and management is a complex procedure including several factors playing major role in healing process. Wounds can mainly be categorized as acute or chronic. It is well referred that the acute wound displays normal wound physiology while healing, in most cases, is seemed to progress through the normal phases of wound healing. On the other hand, a chronic wound is physiologically impaired. The main problem in wound management is that the majority of wounds are colonized with microbes, whereas this does not mean that all wounds will be infected. In this review, we address the problems that clinicians face to manage while treat acute and chronic wounds. Moreover, we demonstrate the pathophysiology, etiology, prognosis and microbiology of wounds. We further introduce the state of art in pharmaceutical technology field as part of wound management aiming to assist health professionals to overcome the current implications on wound assessment. In addition, authors review researches which included the use of gels and dermal films as wound healing agents. It can be said that natural and synthetic drugs or carriers provide promising solutions in order to meet the wound management standards. However, are the current strategies as desirable as medical society wish?

1 June 2016 in Carbohydrate Polymers
Verified
Journal Article
Closed access
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
AZAsimina Zisi
Asimina Zisi
MEMaria K. Exindari
Maria K. Exindari
IKIoannis Karantas
Ioannis Karantas
Dimitrios BikiarisDimitrios Bikiaris
Dimitrios Bikiaris

15 September 2023 in Gels
Verified
Journal Article
Open access
PDF file
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
ECE ÖZCAN BÜLBÜLECE ÖZCAN BÜLBÜL
ECE ÖZCAN BÜLBÜL
MOMehmet Evren Okur
Mehmet Evren Okur
IKIoannis Karantas
Ioannis Karantas
Neslihan Üstündağ OkurNeslihan Üstündağ Okur
Neslihan Üstündağ Okur
The delivery of active molecules via the skin seems to be an efficient technology, given the various disadvantages of oral drug administration. Skin, which is the largest human organ of the body, has the important role of acting as a barrier for pathogens and other molecules including drugs; in fact, it serves as a primary defense system blocking any particle from entering the body. Therefore, to overcome the skin barriers and poor skin permeability, researchers implement novel carriers which can effectively carry out transdermal delivery of the molecules. Another significant issue which medical society tries to solve is the effective dermal delivery of molecules especially for topical wound delivery. The application of nanogels is only one of the available approaches offering promising results for both dermal and transdermal administration routes. Nanogels are polymer-based networks in nanoscale dimensions which have been explored as potent carriers of poorly soluble drugs, genes and vaccines. The nanogels present unique physicochemical properties, i.e., high surface area, biocompatibility, etc., and, importantly, can improve solubility. In this review, authors aimed to summarize the available applications of nanogels as possible vehicles for dermal and transdermal delivery of active pharmaceutical ingredients and discuss their future in the pharmaceutical manufacturing field.


10 November 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
MOMehmet Evren Okur
Mehmet Evren Okur
PEPelin Dilsiz Erim
Pelin Dilsiz Erim
EÇEmre Şefik Çağlar
Emre Şefik Çağlar
EOemre ozgenc
emre ozgenc
Neslihan Üstündağ OkurNeslihan Üstündağ Okur
Neslihan Üstündağ Okur
It has been estimated that every year, millions of people are affected by neurodegenerative disorders, which complicate their lives and their caregivers’ lives. To date, there has not been an approved pharmacological approach to provide the complete treatment of neurodegenerative disorders. The only available drugs may only relieve the symptoms or slow down the progression of the disease. The absence of any treatment is quite rational given that neurodegeneration occurs by the progressive loss of the function or structure of the nerve cells of the brain or the peripheral nervous system, which eventually leads to their death either by apoptosis or necrotic cell death. According to a recent study, even though adult brain cells are injured, they can revert to an embryonic state, which may help to restore their function. These interesting findings might open a new path for the development of more efficient therapeutic strategies to combat devastating neurodegenerative disorders. Gene and protein therapies have emerged as a rapidly growing field for various disorders, especially neurodegenerative diseases. Despite these promising therapies, the complete treatment of neurodegenerative disorders has not yet been achieved. Therefore, the aim of this review is to address the most up-to-date data for neurodegenerative diseases, but most importantly, to summarize the available delivery systems incorporating proteins, peptides, and genes that can potentially target such diseases and pass into the blood–brain barrier. The authors highlight the advancements, at present, on delivery based on the carrier, i.e., lipid, polymeric, and inorganic, as well as the recent studies on radiopharmaceutical theranostics.

1 March 2022 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
MOMehmet Evren Okur
Mehmet Evren Okur
ECE ÖZCAN BÜLBÜLECE ÖZCAN BÜLBÜL
ECE ÖZCAN BÜLBÜL
GMGökçe Mutlu
Gökçe Mutlu
KEKalliopi Eleftherıadou
Kalliopi Eleftherıadou
IKIoannis Karantas
Ioannis Karantas
Panoraia I. SiafakaPanoraia I. Siafaka
Panoraia I. Siafaka
Background &; Objective: Diabetes is a global health problem that has resulted in millions of deaths; one of the most common diabetes complications is that wounds of diabetic patients tend to heal more slowly or may not heal at all, resulting in undesirable outcomes. Diabetic wounds, if become chronic and infected, could provoke lower extremities amputation, sepsis, and even death. Hence, early detection, careful examination, debridement, cleaning, and prevention or controlling the infection of diabetic wounds are important factors for the successful outcome of the case. Over the years, various promising wound dressings incorporating antimicrobial molecules, growth factors, and wound healing agents have been developed, targeting diabetic wounds. Nonetheless, the choice of dressing is mainly based on the experience of each clinician. Summary: This review summarizes the main points of diabetes complications, diabetic wounds, and infections. Further, an overview of the current drug delivery systems for topical wound delivery of various active ingredients has been performed. This update could be helpful for scientists and especially clinicians who desire to plan and work with new strategies for the healing of diabetic wounds.